OTCMKTS:XSNX NovAccess Global (XSNX) Stock Price, News & Analysis → Moonshot Coins for the Current Crypto Run (From Crypto 101 Media) (Ad) Free XSNX Stock Alerts $0.01 0.00 (0.00%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$0.0122▼$0.012250-Day Range$0.0051▼$0.015852-Week Range$0.00▼$0.17Volume12 shsAverage Volume528,743 shsMarket Capitalization$544,156.60P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get NovAccess Global alerts: Email Address Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About NovAccess Global Stock (OTCMKTS:XSNX)NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.Read More XSNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XSNX Stock News HeadlinesJune 13 at 2:08 AM | americanbankingnews.comNovAccess Global Inc. (OTCMKTS:XSNX) Short Interest Up 350.0% in MayMay 21, 2024 | finance.yahoo.comNovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine PlatformMay 7, 2024 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Advisory on Annual Meeting of ShareholdersApril 30, 2024 | finance.yahoo.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformFebruary 7, 2024 | msn.comNovAccess Global Faces Default and Uncertain Rescue DealJanuary 2, 2024 | msn.comNovAccess Global jumps on announcing $10.7 million financingJanuary 2, 2024 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finance.yahoo.comNovAccess Global Announces $10.7 Million FinancingDecember 1, 2023 | finance.yahoo.comNovAccess Global Inc. to Present at the December 7th Virtual Investor SummitNovember 10, 2023 | finance.yahoo.comNovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory BoardNovember 2, 2023 | morningstar.comNovaccess Global Inc XSNXJuly 29, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 27, 2023 | finance.yahoo.comNovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 13, 2023 | finance.yahoo.comNovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness DayJuly 6, 2023 | finance.yahoo.comXSNX - NovAccess Global Inc.June 16, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine DivisionJune 16, 2023 | finance.yahoo.comNovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine DivisionJune 1, 2023 | finance.yahoo.comNovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare TherapiesMay 11, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine AdvancementsMay 11, 2023 | finance.yahoo.comNovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine AdvancementsMarch 15, 2023 | finanznachrichten.deNovAccess Global Inc.: Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon AwardMarch 15, 2023 | finance.yahoo.comDr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon AwardFebruary 16, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global to Present at World Orphan Drug CongressFebruary 16, 2023 | finance.yahoo.comNovAccess Global to Present at World Orphan Drug CongressFebruary 3, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual CongressSee More Headlines Receive XSNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovAccess Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/13/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:XSNX CUSIPN/A CIK1039466 Webwww.xsunx.com Phone(213) 642-9268Fax949-266-5823Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,720,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2,030.05% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-0.02Miscellaneous Outstanding Shares44,603,000Free Float43,961,000Market Cap$544,156.60 OptionableNot Optionable Beta1.86 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Dwain K. Morris-Irvin M.P.H. (Age 56)MPH, Ph.D., CEO & Director Comp: $155.43kMr. Neil J. Laird (Age 71)Chief Financial Officer Dr. Christopher Wheeler Ph.D.President of Stemvax TherapeuticsKey CompetitorsNotable LabsNASDAQ:NTBLMustang BioNASDAQ:MBIOAcura PharmaceuticalsOTCMKTS:ACURGalmed PharmaceuticalsNASDAQ:GLMDClearmind MedicineNASDAQ:CMNDView All Competitors XSNX Stock Analysis - Frequently Asked Questions How have XSNX shares performed in 2024? NovAccess Global's stock was trading at $0.0201 on January 1st, 2024. Since then, XSNX stock has decreased by 39.3% and is now trading at $0.0122. View the best growth stocks for 2024 here. Are investors shorting NovAccess Global? NovAccess Global saw a increase in short interest in May. As of May 31st, there was short interest totaling 1,800 shares, an increase of 350.0% from the May 15th total of 400 shares. Based on an average daily trading volume, of 878,200 shares, the days-to-cover ratio is presently 0.0 days. View NovAccess Global's Short Interest. How were NovAccess Global's earnings last quarter? NovAccess Global Inc. (OTCMKTS:XSNX) announced its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.02) EPS for the quarter. What other stocks do shareholders of NovAccess Global own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN), Ascent Solar Technologies (ASTI) and BioRestorative Therapies (BRTX). How do I buy shares of NovAccess Global? Shares of XSNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:XSNX) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovAccess Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovAccess Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.